{"DataElement":{"publicId":"3756780","version":"1","preferredName":"Protocol Therapy Second Treatment Step Protocol Treatment Arm Assignment Type","preferredDefinition":"the type of treatment assigned during the specific treatment protocol used in the second arm or stage of progression through a sequential treatment protocol_Type; a subdivision of a particular kind of thing","longName":"ST2_PROT_TX_REC","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"3756753","version":"1","preferredName":"Protocol Therapy","preferredDefinition":"the type of treatment assigned during the specific treatment protocol used in the second arm or stage of progression through a sequential treatment protocol","longName":"ST2_PROT_TX_REC","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2211237","version":"1","preferredName":"Protocol Therapy","preferredDefinition":"A protocol is a rule which guides how an activity should be performed; a set of formal rules used to specify the format of an exchange of data.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C42651:C15368","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F38DAD89-EA0D-2FE9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-31","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-03-31","modifiedBy":"ONEDATA","dateModified":"2005-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7318108","version":"1","preferredName":"Unspecified Property","preferredDefinition":"Not stated explicitly or in detail.:A basic or essential attribute shared by all members of a class.","longName":"C38046:C42605","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unspecified","conceptCode":"C38046","definition":"Not stated explicitly or in detail.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Property","conceptCode":"C42605","definition":"A basic or essential attribute shared by all members of a class.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A71D5FBC-8406-6D97-E053-4EBD850AE7DA","latestVersionIndicator":"Yes","beginDate":"2020-06-02","endDate":null,"createdBy":"DWARZEL","dateCreated":"2020-06-02","modifiedBy":"ONEDATA","dateModified":"2020-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC999977-828B-DF0D-E040-BB89AD435D9D","latestVersionIndicator":"Yes","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"GARRIDOJ","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3756775","version":"1","preferredName":"Second Treatment Step Protocol Treatment Arm Assignment Type","preferredDefinition":"the type of treatment assigned during the specific treatment protocol used in the second arm.","longName":"ST2_PROT_TX_REC","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Arm D: Radiotherapy IMRT 66 GY/ 25 Fx (3) + CDDP","valueDescription":"Arm D: Radiotherapy IMRT 66 GY/ 25 Fx (3) + CDDP","ValueMeaning":{"publicId":"3756776","version":"1","preferredName":"Arm D: Radiotherapy IMRT 66 GY/ 25 Fx (3) + CDDP","longName":"3756776","preferredDefinition":"Arm D: Radiotherapy IMRT 66 GY/ 25 Fx (3) + CDDP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC999977-82AE-DF0D-E040-BB89AD435D9D","latestVersionIndicator":"Yes","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC999977-82C7-DF0D-E040-BB89AD435D9D","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"ONEDATA","dateModified":"2013-05-13","deletedIndicator":"No"},{"value":"Arm C: Radiotherapy IMRT 60 GY/30 Fx (3)","valueDescription":"Arm C: Radiotherapy IMRT 60 GY/30 Fx (3)","ValueMeaning":{"publicId":"3756777","version":"1","preferredName":"Arm C: Radiotherapy IMRT 60 GY/30 Fx (3)","longName":"3756777","preferredDefinition":"Arm C: Radiotherapy IMRT 60 GY/30 Fx (3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC999977-82D1-DF0D-E040-BB89AD435D9D","latestVersionIndicator":"Yes","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC999977-82EA-DF0D-E040-BB89AD435D9D","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"ONEDATA","dateModified":"2013-05-13","deletedIndicator":"No"},{"value":"Arm B: Radiotherapy IMRT 50 GY/25 Fx (3)","valueDescription":"Arm B: Radiotherapy IMRT 50 GY/25 Fx (3)","ValueMeaning":{"publicId":"3756778","version":"1","preferredName":"Arm B: Radiotherapy IMRT 50 GY/25 Fx (3)","longName":"3756778","preferredDefinition":"Arm B: Radiotherapy IMRT 50 GY/25 Fx (3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC999977-82F4-DF0D-E040-BB89AD435D9D","latestVersionIndicator":"Yes","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC999977-830D-DF0D-E040-BB89AD435D9D","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"ONEDATA","dateModified":"2013-05-13","deletedIndicator":"No"},{"value":"Arm A: Observation","valueDescription":"Arm A: Observation","ValueMeaning":{"publicId":"3756779","version":"1","preferredName":"Arm A: Observation","longName":"3756779","preferredDefinition":"Arm A: Observation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC999977-8317-DF0D-E040-BB89AD435D9D","latestVersionIndicator":"Yes","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DC999977-8330-DF0D-E040-BB89AD435D9D","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"ONEDATA","dateModified":"2013-05-13","deletedIndicator":"No"},{"value":"Arm D: ChemoRT alone","valueDescription":"Protocol Treatment Arm Chemoradiotherapy Single","ValueMeaning":{"publicId":"6942253","version":"1","preferredName":"Protocol Treatment Arm Chemoradiotherapy Single","longName":"6942253","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. : Not accompanied by another or others; exclusive of anyone or anything else.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemoradiotherapy","conceptCode":"C94626","definition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92E85637-1A35-6F32-E053-F662850AE959","latestVersionIndicator":"Yes","beginDate":"2019-09-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92E85637-1A50-6F32-E053-F662850AE959","beginDate":"2019-09-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Arm C: ChemoRT + Durvalumab","valueDescription":"Protocol Treatment Arm Chemoradiotherapy And Durvalumab","ValueMeaning":{"publicId":"6942254","version":"1","preferredName":"Protocol Treatment Arm Chemoradiotherapy And Durvalumab","longName":"6942254","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. : An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Chemoradiotherapy","conceptCode":"C94626","definition":"Treatment that combines chemotherapy with radiation therapy. Chemoradiation can be concurrent or sequential. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92E85637-1A5F-6F32-E053-F662850AE959","latestVersionIndicator":"Yes","beginDate":"2019-09-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92E85637-1A7A-6F32-E053-F662850AE959","beginDate":"2019-09-19","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Arm B: Hyper CVAD + Steroids + TKI","valueDescription":"Protocol Treatment Arm HyperCVAD Regimen Steroid Compound Tyrosine Kinase Inhibitor","ValueMeaning":{"publicId":"7426135","version":"1","preferredName":"Protocol Treatment Arm HyperCVAD Regimen Steroid Compound Tyrosine Kinase Inhibitor","longName":"7426135","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma.: A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed): Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"HyperCVAD Regimen","conceptCode":"C63455","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Steroid Compound","conceptCode":"C843","definition":"Compounds possessing the skeleton of cyclopenta[a]phenanthrene or a skeleton derived therefrom by one or more bond scissions or ring expansions or contractions. Methyl groups are normally present at C-10 and C-13. An alkyl side chain may also be present at C-17.  They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF9AF5C4-F986-7A2E-E053-4EBD850A43DF","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B010A911-D29C-1FEC-E053-4EBD850A09D6","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Arm C: Blinatumomab + TKI","valueDescription":"Protocol Treatment Arm Blinatumomab Tyrosine Kinase Inhibitor","ValueMeaning":{"publicId":"7426134","version":"1","preferredName":"Protocol Treatment Arm Blinatumomab Tyrosine Kinase Inhibitor","longName":"7426134","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.: A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.: Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF9AF5C4-F95C-7A2E-E053-4EBD850A43DF","latestVersionIndicator":"Yes","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AF9AF5C4-F977-7A2E-E053-4EBD850A43DF","beginDate":"2020-09-18","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2020-09-18","modifiedBy":"ONEDATA","dateModified":"2020-09-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC999977-829B-DF0D-E040-BB89AD435D9D","latestVersionIndicator":"Yes","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"GARRIDOJ","dateModified":"2020-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811912","version":"1","longName":"Head and Neck","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]}],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"What treatment did the patien","type":"Preferred Question Text","description":"What treatment did the patient receive on step 2?","url":null,"context":"ECOG-ACRIN"},{"name":"OPEN Checklist","type":"Alternate Question Text","description":"Treatment Arm in Step 2","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DC999977-833A-DF0D-E040-BB89AD435D9D","latestVersionIndicator":"Yes","beginDate":"2013-05-13","endDate":null,"createdBy":"VIENNEAM","dateCreated":"2013-05-13","modifiedBy":"GARRIDOJ","dateModified":"2019-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}